Contraindications: Testopin-100 must not be used by individuals with diagnosed prostate or breast carcinoma, severe hepatic impairment, untreated polycythaemia, or hypersensitivity to Testosterone Propionate or any carrier oil component. Individuals under 18 years of age must not use this product. Those with a history of sleep apnoea, uncontrolled hypercalcaemia, or active thromboembolic events should seek specialist advice before any exogenous testosterone administration.
Side Effects: Exogenous testosterone suppresses endogenous LH and FSH via hypothalamic-pituitary feedback, leading to testicular atrophy and impaired spermatogenesis during the cycle. Androgenic effects including acne, accelerated androgenetic alopecia, and increased sebum production may occur. Aromatisation to oestradiol can produce gynaecomastia, water retention, and mood instability — risk is lower than with longer-ester testosterones due to shorter active periods, but remains present. Elevated haematocrit is a cardiovascular concern with sustained use.
Monitoring: Full blood panel — including serum testosterone, oestradiol, haematocrit, liver enzymes (ALT/AST), lipid profile, and PSA — is recommended before cycle initiation and every 4 weeks thereafter. Blood pressure should be self-monitored at least weekly. Haematocrit above 54% warrants immediate dose reduction or cycle cessation.
PCT: Post-cycle therapy is required after any Testosterone Propionate cycle. Because Propionate clears rapidly (testosterone returns toward baseline within 4–7 days of the last injection), PCT with a SERM such as Tamoxifen (Nolvadex) or Clomiphene Citrate can begin 3–5 days after the final dose — considerably sooner than the 2-week delay required after long-ester testosterone cycles. Standard SERM protocols of 4–6 weeks are recommended to restore endogenous axis function.